06.22.26 -- Remember Why You Are Outsourcing

Developability assessments flag early risks in stability, manufacturability, and biophysics, helping teams focus on candidates most likely to succeed clinically and commercially.

Explore chromatography fundamentals, resin selection strategies, and the regulatory frameworks required to qualify automated systems for compliant, commercial-scale biologics manufacturing.

Discover how knowledge of microbial processes and process characterization understanding can be used to design targeted BLA programs while managing risks.

Assimilate how applying an OpEx framework to environmental monitoring and sample management can optimize workflows, improve resource utilization, and deliver measurable annual cost savings.

Ensuring container closure integrity in an increasingly complex pharmaceutical industry requires a holistic approach that incorporates quality control into all phases of product design and development.

Uncover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.

Evolving regulations require proactive impurity control using trace‑level detection, solid risk assessment, advanced analytics, and ongoing monitoring to prevent compliance issues.

Rapid analytical testing turnaround is essential to maintaining development timelines, meeting clinical milestones, and in commercial manufacturing, providing reliable drug supply to patients.

See where tech transfer and validation commonly falter, and how disciplined execution helps teams maintain control through PPQ and beyond.

Commercial success comes from treating tech transfer as a strategic collaboration. Flexible processes, early supply chain planning, and partnerships protect timelines and drive long‑term performance.

Leverage a platform-based analytical development strategy to accelerate ADC IND readiness through early CQA identification, reduced development risk, and streamlined progression.

Europe’s integrated CDMO model is reshaping biologics development by aligning early science, manufacturing, and quality to accelerate scalable, compliant therapies from concept to clinic.

At AAPS, drug product experts discuss how formulation, stability, and analytical services enable robust CMC strategies, reduce development risk, and support confident regulatory decision‑making.